Therapy

Response of HIV RNA to ddI Predictive of Survival

Published in AIDS Weekly, March 20th, 1995

In patients treated with didanosine (ddI), changes in viremia at one month after initiation of therapy predict survival independently of initial AIDS diagnosis and initial CD4 count, according to a report from Switzerland.

The benefits of treatment for HIV-positive persons diminish with time and there has been much concern in case development of viral resistance limits the effectiveness of antiretroviral drugs.

In an earlier study researcher Sabine Yerly and colleagues showed that in a group of 14 ddI-treated patients, a fall in viremia in the first month of therapy predicts a persisting decrease in viremia for the following year.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-03-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry